{"id":39820,"date":"2026-03-27T15:06:22","date_gmt":"2026-03-27T15:06:22","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/39820\/"},"modified":"2026-03-27T15:06:22","modified_gmt":"2026-03-27T15:06:22","slug":"novartis-to-acquire-excellergy-strengthening-allergy-pipeline-with-next-generation-anti-ige-therapy","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/39820\/","title":{"rendered":"Novartis to acquire Excellergy, strengthening allergy pipeline with next-generation anti-IgE therapy"},"content":{"rendered":"<p>    <img fetchpriority=\"high\" decoding=\"async\" src=\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/03\/6b750a9ec2219e49b0df61c70cca34eb.jpeg\" alt=\"Novartis to acquire Excellergy, strengthening allergy pipeline with next-generation anti-IgE therapy\" loading=\"eager\" height=\"443\" width=\"960\" class=\"yf-lglytj  loaded\"\/> Novartis to acquire Excellergy, strengthening allergy pipeline with next-generation anti-IgE therapy Proactive uses images sourced from Shutterstock      <\/p>\n<p class=\"yf-1fy9kyt\"><a href=\"https:\/\/finance.yahoo.com\/quote\/NVS\" data-ylk=\"slk:Novartis AG (ADR) (NYSE:NVS);elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yLinkText&quot;:&quot;Novartis AG (ADR) (NYSE&quot;}\" class=\"link \" rel=\"nofollow noopener\" target=\"_blank\">Novartis AG (ADR) (NYSE:NVS)<\/a> announced an agreement to acquire Excellergy, a private biotech company developing next-generation anti-IgE therapies for allergic diseases.<\/p>\n<p class=\"yf-1fy9kyt\">Under the agreement, Novartis will pay up to US$2 billion in upfront and milestone payments for Excellergy.<\/p>\n<p class=\"yf-1fy9kyt\">The acquisition is set to add Exl-111, a half-life extended, high-affinity anti-IgE antibody currently in Phase 1, to Novartis\u2019 allergy portfolio.<\/p>\n<p class=\"yf-1fy9kyt\">Novartis said the deal supports its immunology strategy, particularly in food allergy and other IgE-driven conditions. Exl-111 is designed to dissociate receptor-bound IgE, potentially offering faster and deeper suppression of IgE signaling compared with conventional anti-IgE therapies. Preclinical data and early human pharmacokinetics indicate sustained exposure consistent with its half-life\u2011extended design.<\/p>\n<p class=\"yf-1fy9kyt\">\u201cExcellergy adds a differentiated next-generation anti-IgE program that builds on biology Novartis knows well, supported by preclinical evidence and early clinical pharmacokinetic data,\u201d\u00a0said Fiona Marshall, President of Biomedical Research at Novartis.<\/p>\n<p class=\"yf-1fy9kyt\">\u201cThis proposed acquisition strengthens our allergy portfolio and reflects our strategy of advancing innovative bold science to bring meaningful additional benefits to patients.\u201d<\/p>\n<p class=\"yf-1fy9kyt\">The acquisition is expected to close in the second half of 2026, subject to customary closing conditions and regulatory approvals.<\/p>\n<p class=\"yf-1fy9kyt\">Shares of Novartis were little changed on the news, trading hands at $150.<\/p>\n","protected":false},"excerpt":{"rendered":"Novartis to acquire Excellergy, strengthening allergy pipeline with next-generation anti-IgE therapy Proactive uses images sourced from Shutterstock Novartis&hellip;\n","protected":false},"author":2,"featured_media":39821,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[23164,23302,23301,206],"class_list":["post-39820","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-excellergy","tag-fiona-marshall","tag-food-allergy","tag-novartis"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116301764046088347","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/39820","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=39820"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/39820\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/39821"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=39820"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=39820"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=39820"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}